Genentech is pouring roughly $750 million into its Hillsboro campus to double the size of its existing fill-finish plant, a project the biotech company says will eventually create about 450 jobs in Washington County. The expansion will add end-to-end device filling capabilities for pre-filled syringes and autoinjectors, but commercial operations are not expected to begin until 2031.
The new manufacturing line will produce outpatient drug-delivery devices in support of parent company Roche's push into obesity and metabolic care, where Roche is advancing five mid- to late-stage drug candidates, according to BioSpace. As KOIN.com reported, Genentech says the Hillsboro campus is a critical hub for its U.S. production, and the expansion will give the company added flexibility to support a growing drug pipeline. The initial figure cited in some early reporting put the investment at $75 million, but official releases and industry outlets have since confirmed the actual figure is $750 million.
Construction Jobs Now, Manufacturing Roles Years Away
According to Business Oregon, the project includes 200 construction jobs in the near term, followed by roughly 250 high-wage manufacturing positions once the facility is operational. The station's report notes the broader estimate of about 450 total jobs for the Hillsboro area tied to the buildout. That timeline reflects the long lead time required to bring specialized pharmaceutical manufacturing online, since construction work begins immediately while commercial production waits until 2031.
Oregon Gov. Tina Kotek said the expansion will help strengthen the region's economic growth, per the same account relayed by KOIN.com. Her administration has emphasized creating new good-paying jobs, strengthening Oregon's economic foundation, and ensuring families and communities benefit from the new opportunity. Kotek toured Genentech's Hillsboro campus just weeks before this news, a visit that came ahead of the expansion announcement.
A Two-Decade Footprint in Washington County
Genentech first acquired its 75-acre Hillsboro property in December 2006 and opened operations there in April 2010 following an initial $400 million investment, according to LifeScienceHistory.com. The company completed a $125 million expansion of the site in 2015. As of January 2026, the campus employed more than 800 people across its Hillsboro Technical Operations and Hillsboro Individualized Therapies divisions, per Genentech.
Beyond manufacturing, the Hillsboro site also houses a distribution hub that supplies one-third of Roche's U.S. pharmaceutical market and manages bulk tank logistics for Roche's global drug substance network, according to Genentech. That existing footprint underscores why the company is choosing to build out device-filling capacity in Oregon rather than starting fresh elsewhere.
Oregon Piece Fits a Bigger Roche Puzzle
The Hillsboro announcement closely follows Genentech completing the structural framework for a $2 billion biomanufacturing facility in Holly Springs, North Carolina, dedicated to producing metabolic medicines, as reported by Pharma Manufacturing. While North Carolina will handle active biologics production, Hillsboro is positioned to provide the specialized end-to-end device fill-finish work for the syringes and autoinjectors that ultimately reach patients. Hoodline previously covered that $2 billion Wake County buildout.
Across the country, Swiss parent company Roche Group operates 13 manufacturing sites and 15 research and development sites, employing roughly 25,000 workers as part of a $50 billion U.S. investment commitment, according to DCAT Value Chain Insights. The Hillsboro and Holly Springs investments also stand in contrast to Genentech's 2024 divestment of its Vacaville, California bulk biologics plant, which the company sold to Lonza for $1.2 billion as it shifted capital toward specialized fill-finish and device manufacturing hubs, per Fierce Pharma.
Why Oregon Keeps Betting on Bioscience
State benchmarks help explain why Oregon officials are courting this kind of investment so aggressively. The Oregon Bioscience Association's 2025 Economic Impact Report found the state's private bioscience industry directly employed 20,783 workers in 2023 across nearly 2,000 establishments, with average annual research wages of $92,114 — well above general state pay levels. Business Oregon reported in October 2025 that, including multiplier effects, the bioscience sector supports 75,000 jobs and $21.2 billion in economic output statewide, with bioscience exports up 130% over the past decade.
Genentech describes itself as a biotech company that develops medicines for serious and life-threatening illnesses, and the Hillsboro expansion builds on Oregon's existing bioscience and advanced manufacturing base. With commercial operations still five years out, the immediate impact for Washington County will be construction activity, while the promised wave of permanent, high-wage manufacturing jobs remains on the horizon for 2031.
